Abstract
Oscillatory activity in the entorhinal cortex has been associated with several cognitive functions. Accordingly, Alzheimer Disease-associated cognitive decline has been related to amyloid beta-induced disturbances in several of these oscillatory patterns. We have previously shown that acute application of amyloid beta inhibits the generation of slowfrequency oscillations (7-20 Hz). In contrast, alterations in faster oscillations recorded in Alzheimer Disease-transgenic mice that over-express amyloid beta have been controversial. Since transgenic mice may produce complex responses due to compensatory mechanisms, we tested the effect of acute application of amyloid beta on fast oscillations (beta-gamma bursts) generated by entorhinal cortex slices in vitro in a Mg2+-free solution. We also explored the participation of the enzyme glycogen synthase kinase 3 (GSK-3) in this effect. Our results show that bath application of a clinically relevant concentration of amyloid beta (10 nM) activates GSK-3 and reduces the power of beta-gamma bursts in the entorhinal cortex. The reduction of beta-gamma bursts by amyloid beta is blocked by inhibiting GSK-3 either with lithium or with SB 216763. Our results suggest that amyloid beta-induced inhibition of entorhinal cortex beta-gamma activity involves GSK-3 activation, which may provide a molecular mechanism for amyloid beta-induced neural network disruption and support the use of GSK-3 inhibitors to treat Alzheimer Disease.
Keywords: Alzheimer’s disease, gamma oscillations, network activity, amyloid beta protein, GSK-3, lithium, depression.
Current Alzheimer Research
Title:Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3
Volume: 9 Issue: 7
Author(s): Fernando Pena-Ortega, Angeles Solis-Cisneros, Benito Ordaz, Hugo Balleza-Tapia and Juan Javier Lopez-Guerrero
Affiliation:
Keywords: Alzheimer’s disease, gamma oscillations, network activity, amyloid beta protein, GSK-3, lithium, depression.
Abstract: Oscillatory activity in the entorhinal cortex has been associated with several cognitive functions. Accordingly, Alzheimer Disease-associated cognitive decline has been related to amyloid beta-induced disturbances in several of these oscillatory patterns. We have previously shown that acute application of amyloid beta inhibits the generation of slowfrequency oscillations (7-20 Hz). In contrast, alterations in faster oscillations recorded in Alzheimer Disease-transgenic mice that over-express amyloid beta have been controversial. Since transgenic mice may produce complex responses due to compensatory mechanisms, we tested the effect of acute application of amyloid beta on fast oscillations (beta-gamma bursts) generated by entorhinal cortex slices in vitro in a Mg2+-free solution. We also explored the participation of the enzyme glycogen synthase kinase 3 (GSK-3) in this effect. Our results show that bath application of a clinically relevant concentration of amyloid beta (10 nM) activates GSK-3 and reduces the power of beta-gamma bursts in the entorhinal cortex. The reduction of beta-gamma bursts by amyloid beta is blocked by inhibiting GSK-3 either with lithium or with SB 216763. Our results suggest that amyloid beta-induced inhibition of entorhinal cortex beta-gamma activity involves GSK-3 activation, which may provide a molecular mechanism for amyloid beta-induced neural network disruption and support the use of GSK-3 inhibitors to treat Alzheimer Disease.
Export Options
About this article
Cite this article as:
Pena-Ortega Fernando, Solis-Cisneros Angeles, Ordaz Benito, Balleza-Tapia Hugo and Javier Lopez-Guerrero Juan, Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3, Current Alzheimer Research 2012; 9 (7) . https://dx.doi.org/10.2174/156720512802455403
DOI https://dx.doi.org/10.2174/156720512802455403 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Epigenomic Approach in Understanding Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
Current Alzheimer Research Editorial (Thematic Issue: Medicinal Chemistry: Neurological and Endocrinological Disorders)
Medicinal Chemistry Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Telephone Follow-up of Older People After Hospital Admissions
Current Aging Science Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry Inappropriate Antidopaminergic Drug Use in Parkinson’s Disease Inpatients
Current Drug Therapy Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease
Current Psychiatry Reviews Mechanisms of Synaptic Homeostasis in Alzheimers Disease
Current Alzheimer Research Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews